With a revenue increase of 9.72% in the first quarter 2026, year on year to cumulative value of $1,095 million, Acadia Pharmaceuticals Inc 's revenue per employee grew on a trailing twelve months basis to $ 1,372,494, this marks a new company high. Within the Healthcare sector Employees of 40 other companies have achieved higher revenue per employee. While Acadia Pharmaceuticals Inc 's total ranking has deteriorated compared to the previous quarter from 0 to 444. Acadia Pharmaceuticals Inc has 798 employees.
Acadia Pharmaceuticals Achieves New Revenue Milestone Amid Priority Review Voucher Sale Acadia Pharmaceuticals Inc. a prominent player in the healthcare sector, has announced the successful closing of its sale of a Rare Pediatric Disease Priority Review Voucher, generating proceeds of $150 million. This substantial transaction marks yet another milestone for the company, reflecting its strategic alignment with growth opportunities in the pharmaceutical industry.On a broader scale, Acadia s financial performance has exhibited robust growth, particularly evidenced by the increase in revenue per employee. On a trailing twelve months basis, this figure has surged to $1,553,906, marking an 18.28% increase in the third quarter of 2024 compared to the same period last year. The cumulative revenue reached $929 million, representing a new high for the company.
In a significant development for the pharmaceutical landscape, Acadia Pharmaceuticals Inc. has announced an exclusive worldwide licensing agreement with Saniona for the development and commercialization of SAN711, a novel treatment aimed at addressing essential tremor, a debilitating neurological condition. The deal positions Acadia at the forefront of innovation in the realm of neurology, where effective treatments for essential tremor remain limited.SAN711 is described as a first-in-class, highly selective GABAA-3 positive allosteric modulator. This cutting-edge formulation hints at Acadia s commitment to employ advanced science to tackle unmet medical needs. Essential tremor, which affects millions of people, manifests as involuntary shaking or trembling movements, often impairing everyday activities such as eating, writing, or even holding a drink. The collaboration with Saniona may propose a beacon of hope for those suffering from this condition, providing potential relief and an improved quality of life.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
